Can a Doctor Prescribe BPC-157 in 2026? What the PCAC Vote Changed, and What It Didn't

The short answer

A licensed prescriber can write a prescription for anything, including BPC-157. Whether a pharmacy can lawfully fill it is a different question, and as of September 30, 2026 the answer for a compounded US product is no.

That is the gap most coverage of the July vote skipped. The committee recommended BPC-157, but a recommendation is not a rule. Until FDA either places BPC-157 in Category 1 of its nominated substances or adds it to the 503A bulks list through regulation, a compounding pharmacy has no lawful way to make it ¹.

BPC-157 is also not an approved drug, so there is no manufactured product to prescribe instead. What is sold online as BPC-157 is sold as a research chemical, outside both routes.

How a compounding pharmacy is allowed to use a substance

A 503A pharmacy, the kind that compounds a drug for an individual patient on a prescription, may use a bulk drug substance in only three situations. FDA's interim policy quotes them from the statute: the substance has an applicable USP or National Formulary monograph; or, if no monograph exists, it is a component of a drug FDA has approved; or, failing both, it appears on a list the Secretary develops through regulations under section 503A ¹.

BPC-157 meets none of the three. It has no USP monograph. It is not a component of any approved drug, because no BPC-157 drug has ever been approved. And the third route, the 503A bulks list, is the one the July vote was about.

The bulks list is built slowly, through notice-and-comment rulemaking. To bridge that, FDA uses an interim policy: it does not intend to take regulatory action against a 503A pharmacy compounding with a substance that has no monograph and is not in an approved drug, if, among other conditions, the substance appears in Category 1 of FDA's nominated-substances list ¹. Category 1 is therefore the practical door. BPC-157 is not in it.

How BPC-157 got here

The July vote did not come out of nowhere. BPC-157 had sat in Category 2 of FDA's nominated-substances list, the category for substances that raise significant safety risks, after FDA reviewed its nominations. FDA's published summary of the risks says compounded BPC-157 may pose a risk of immunogenicity for certain routes of administration, may have complexities with peptide-related impurities and characterising the active ingredient, and that the agency has no, or only limited, safety information for the proposed routes ². The nominations for BPC-157 and several other peptides were then withdrawn, which removed them from Category 2, and new nominations sent them to the advisory committee for a fresh look ³.

That sequence explains why BPC-157 appears in none of the three categories today. It has left the safety-concern list without arriving on the under-evaluation list. The committee's recommendation is the next step in a process FDA has not finished, and the substance's regulatory position is, in a precise sense, unresolved rather than favourable.

FDA's own briefing documents for the July meeting set out the agency staff's reasoning compound by compound, and they are worth reading alongside the vote: the committee recommended several peptides over the view of the FDA staff who reviewed them. Those documents are linked from the meeting page and from each compound's page on our PCAC hub ⁴.

What the committee actually voted

The Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, to consider seven peptides for the 503A bulks list. It recommended six and rejected one ⁴.

The margins were narrow. Three of the recommendations passed by two votes, and FDA has not published minutes, so every tally here is as reported by the trade and legal press; the reports agree on everything except epitalon's 'no' count, which is given as 4 by two sources and 5 by a third. The outcome is not in dispute.

Two things are worth noticing in that table. Every recommended compound except semax carries our lowest evidence grade, and the committee's own split mirrors that: a recommendation to allow compounding is not a finding that a substance works. It is a judgement that the substance can be compounded under pharmacy oversight, which is a much lower bar than approval. The full vote record, with each compound's briefing, is on our PCAC hub.

What FDA has done since

Nothing that changes access, as of September 30, 2026. We checked each of the places an action would appear.

The nominated-substances list. FDA's list of bulk drug substances nominated for 503A compounding still reads 'Updated May 14, 2026'. None of the seven compounds the committee considered appears in any of its three categories. Category 2, the list of substances raising significant safety risks, now names only cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine for intrauterine use ³.

The Federal Register. Adding a substance to the 503A bulks list requires a rule, and a rule begins with a proposal published in the Federal Register. No FDA document on 503A bulk drug substances has been published there since July 1, 2026 ⁵.

The meeting record. FDA's page for the July meeting was last updated on August 6, 2026, and carries no minutes or transcript ⁴. The 503A list itself says FDA intends to consult the committee again before the end of February 2027, on a different substance ³.

The absence from Category 2 is easy to misread. BPC-157 had been in Category 2 before its nominations were withdrawn and resubmitted for committee review; not being in Category 2 today does not mean FDA has cleared it. It means BPC-157 is in none of the categories, which leaves it outside the interim policy altogether.

The access reality, step by step

For a patient asking whether they can get BPC-157 through a doctor, the chain looks like this as of September 30, 2026.

1. The prescription. A prescriber can write one. Nothing in the law stops the act of writing it.
2. An approved product. There is none. No BPC-157 drug has been approved by FDA or by any other national regulator, so no pharmacy can dispense a manufactured product.
3. A 503A compounding pharmacy. It may use a bulk substance only through a monograph, an approved-drug component, or the bulks list, and in practice Category 1 under the interim policy. BPC-157 has none of these, so a 503A pharmacy has no lawful basis to compound it ¹.
4. A 503B outsourcing facility. These operate under a separate statutory section with its own bulks list and its own criteria. The July vote concerned the 503A list and does not open this route either.
5. Research chemicals. Products labelled 'for research use only, not for human consumption' sit outside drug regulation entirely. Buying one is not obtaining a prescription drug, whatever the seller's site implies.

The same chain applies to the other five recommended compounds, with one difference for semax, which is registered as a medicine in Russia but not approved in the US. A foreign registration does not make a substance a component of an FDA-approved drug.

What to make of clinics that offer it

Some telehealth services and clinics advertise BPC-157 as a prescription product. Given the chain above, that claim deserves a direct question: which pharmacy fills it, and under which of the three statutory routes? A pharmacy cannot lawfully compound BPC-157 under section 503A while it is outside Category 1 and off the bulks list, so a service that supplies it is relying on something other than that route.

The answer may be a research-chemical supplier, an overseas source, or a reading of the rules FDA does not share. None of those is the same as a prescription drug dispensed by a US pharmacy under FDA's framework, and a patient is entitled to know which it is before injecting anything. FDA has sent warning letters to online sellers marketing unapproved peptides, and our regulatory tracker logs them as they are published.

None of this is a judgement about the people who want BPC-157, many of whom have tried conventional treatment for an injury or a gut condition and found it wanting. It is a description of where the legal line sits as of September 30, 2026, so that the choice is made with the facts in view.

What would change the answer

Two FDA actions would open the 503A route, and either would be visible on the day it happened. FDA could move BPC-157 into Category 1 of the nominated-substances list, which would bring it under the interim policy while the bulks-list rule proceeds; that is an administrative change to a web document. Or FDA could publish a proposed rule in the Federal Register to add it to the 503A bulks list, which starts notice and comment.

FDA is not bound by the committee. It has declined advisory committee recommendations before, in both directions, and the briefing documents its own staff prepared for July did not recommend most of the seven. A recommendation narrowly passed over FDA staff's view is exactly the kind FDA may sit on.

We re-read the list, the Federal Register and the meeting page at every regulatory watch, and this article is re-dated each time. The regulatory tracker carries the current status of every compound the committee considered.

Why the evidence question has not gone away

Compounding access and evidence of benefit are separate questions, and the July vote settled neither for good. BPC-157's published record is overwhelmingly animal and cell work; our encyclopedia entry lists what exists in people, which is a handful of small, uncontrolled reports and no randomised trial for any condition.

The same is true, to varying degrees, of most of the six. That is why a committee vote to permit compounding sits awkwardly beside the evidence grades in the table above: the committee was asked whether these substances may be compounded, not whether they work. A patient weighing BPC-157 should hold those two answers apart.

For sport, the question is closed regardless of compounding. BPC-157 is prohibited at all times under WADA's catch-all S0 section, by name in the list's own examples ⁶.

Frequently asked questions

Can a doctor prescribe BPC-157?

A doctor can write the prescription, but as of September 30, 2026 no US pharmacy has a lawful path to fill it as a compounded drug, and there is no approved BPC-157 product to dispense.

Is BPC-157 legal in the US?

It is not an approved drug and cannot lawfully be compounded by a 503A pharmacy as of September 30, 2026. It is sold online as a research chemical labelled not for human use, which is not a prescription route.

Did FDA approve BPC-157 in 2026?

No. FDA's compounding advisory committee recommended adding it to the 503A bulks list in July 2026, by 8 votes to 6 with 1 abstention. That is advice to FDA, which had not acted as of September 30, 2026.

What would make BPC-157 available from a compounding pharmacy?

FDA moving it into Category 1 of its nominated-substances list, or publishing a rule adding it to the 503A bulks list. Neither had happened as of September 30, 2026.

Is BPC-157 allowed in sport?

No. WADA prohibits it at all times under section S0, which covers substances with no current approval for human therapeutic use.

Related on Grey Peptides

• BPC-157 encyclopedia entry
• PCAC July 2026 hub
• What research use only means
• BPC-157 complete guide
• Regulatory tracker

Sources

1. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Guidance for industry, January 2025. Read September 30, 2026. FDA
2. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: BPC-157. Content current as of April 22, 2026; read September 30, 2026. FDA
3. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Categories 1, 2 and 3). Updated May 14, 2026; read September 30, 2026. FDA
4. U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: agenda, roster and briefing documents. Content current as of August 6, 2026; read September 30, 2026. Vote tallies as reported by Hyman, Phelps & McNamara, McDermott and RAPS Regulatory Focus; FDA has not posted minutes. FDA
5. Federal Register. Search of FDA documents on 503A bulk drug substances published since July 1, 2026: none found. Read September 30, 2026. Federal Register
6. World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S0, non-approved substances. WADA

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. This article describes regulatory status and is not legal or medical advice; a prescriber and a licensed pharmacist are the people to ask about a specific case.